Mesothelioma Related Clinical Trials:
Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer.

• Maximum tolerated dose (MTD) as measured by unacceptable toxicity. [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
  

• Assess the safety and tolerability after 14 consecutive day administration followed by 7 days of rest in repeated 21 day cycles as measured by disease progression or unacceptable toxicity. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

• Patient must be 18 years or older with confirmed diagnosis of a solid tumor for which pemetrexed/cisplatin is acceptable treatment but has yet been previously treated with systemic therapy or has failed standard first-line therapy
• Has at least 1 measurable lesion
• Has adequate blood, liver, and kidney functions
• Has not received any chemotherapy for at least 4 weeks prior to entry in this study
• Agrees to take adequate measures to prevent pregnancy as outlined in the protocol

Exclusion Criteria:

• Patient has been treated with other investigational agents with a similar anti-tumor mechanism
• Patient should not have failed more than 1 prior treatment regimen
• Patient has active infection or had received IV (intravenous) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs
• Patient has HIV, hepatitis B or hepatitis C infection
• Patient is pregnant or breast feeding.
• Patient has allergy to any component of the study drugs
• Patient has history of GI (gastrointestinal) surgery or conditions